Natriuretic peptides in cardiovascular diseases: Current use and perspectives

Massimo Volpe, Speranza Rubattu, John C Jr. Burnett

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF.The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.

Original languageEnglish (US)
JournalEuropean Heart Journal
Volume35
Issue number7
DOIs
StatePublished - Feb 2014

Fingerprint

Natriuretic Peptides
Cardiovascular Diseases
Heart Failure
Hypertension
Coronary Artery Disease
C-Type Natriuretic Peptide
Hormones
Left Ventricular Hypertrophy
Atrial Natriuretic Factor
Cardiovascular System
Vasodilator Agents
Diuretics
Hemodynamics
Stroke
Pharmacology
Therapeutics
Genes

Keywords

  • ARNi
  • Cardiovascular diseases
  • Genetics
  • Natriuretic peptides
  • Natriuretic peptides analogues
  • NEP inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Natriuretic peptides in cardiovascular diseases : Current use and perspectives. / Volpe, Massimo; Rubattu, Speranza; Burnett, John C Jr.

In: European Heart Journal, Vol. 35, No. 7, 02.2014.

Research output: Contribution to journalArticle

@article{5d4e35fba57f4b318f0dd3e074b363ec,
title = "Natriuretic peptides in cardiovascular diseases: Current use and perspectives",
abstract = "The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF.The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.",
keywords = "ARNi, Cardiovascular diseases, Genetics, Natriuretic peptides, Natriuretic peptides analogues, NEP inhibitors",
author = "Massimo Volpe and Speranza Rubattu and Burnett, {John C Jr.}",
year = "2014",
month = "2",
doi = "10.1093/eurheartj/eht466",
language = "English (US)",
volume = "35",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Natriuretic peptides in cardiovascular diseases

T2 - Current use and perspectives

AU - Volpe, Massimo

AU - Rubattu, Speranza

AU - Burnett, John C Jr.

PY - 2014/2

Y1 - 2014/2

N2 - The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF.The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.

AB - The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF.The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.

KW - ARNi

KW - Cardiovascular diseases

KW - Genetics

KW - Natriuretic peptides

KW - Natriuretic peptides analogues

KW - NEP inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84894256771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894256771&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/eht466

DO - 10.1093/eurheartj/eht466

M3 - Article

C2 - 24227810

AN - SCOPUS:84894256771

VL - 35

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 7

ER -